Announced
Financials
Tags
Single Bidder
Private
United States
Friendly
Reverse Takeover
Acquisition
Domestic
drug delivery
De-SPAC
Merger
Majority
Pharmaceuticals
Failed
Synopsis
Aerami Therapeutics, a developer of therapies intended for the treatment of severe respiratory and chronic diseases, terminated its merger with FoxWayne Enterprises Acquisition in a $250m deal. Aerami and FoxWayne believe that terminating the business combination agreement is the best path forward for the parties and their respective stockholders.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.